Institution
Chiron Corporation
About: Chiron Corporation is a based out in . It is known for research contribution in the topics: Antigen & Hepatitis C virus. The organization has 1973 authors who have published 1969 publications receiving 172330 citations.
Topics: Antigen, Hepatitis C virus, Virus, Antibody, Peptide sequence
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Yap3 and Mkc7 proteases are alpha-secretases which act on APP in the late Golgi which suggest that GPI-linked aspartyl proteases should be investigated as candidate secretases in mammalian tissues.
67 citations
•
30 Nov 1994TL;DR: In this paper, the integration of heterologous DNA into yeast genomic DNA is accomplished at high copy number by targeting integration vectors to dispersed repetitive elements such as DELTA sequences, Ty elements, or tRNA DNA sequences present in the host cell genome.
Abstract: Efficient integration of heterologous DNA into yeast genomic DNA is accomplished at high copy number by targeting integration vectors to dispersed repetitive elements such as DELTA sequences, Ty elements, or tRNA DNA sequences present in the host cell genome.
67 citations
••
TL;DR: Intraperitoneal treatment with dl1520 led to complete tumor eradication and/or significantly improved survival in two p53(−) nude mouse–human ovarian tumor xenograft models, and no efficacy was seen with non-replicating/UV-inactivated dl 1520.
Abstract: Intraperitoneal (i.p.) recurrence of cisplatin-refractory and p53 mutant ovarian cancer is a major clinical problem, despite surgery and chemotherapy. dl1520 (ONYX-015) is an E1B–55 kDa gene-deleted adenovirus engineered selectively to replicate in and destroy cancer cells lacking functional p53. However, a correlation between efficacy and p53 function has not been definitively studied in vivo to date, and efficacy following i.p. administration had not been previously described. We therefore carried out experiments to address these issues in three nude mouse–human ovarian carcinomatosis xenograft models. Intraperitoneal treatment with dl1520 led to complete tumor eradication and/or significantly improved survival in two p53(−) nude mouse–human ovarian tumor xenograft models. OVCAR3 i.p. xenografts underwent complete regressions in 11 of 12 mice (versus one of seven controls; P = 0.001), while mice bearing cisplatin-resistant A2780 tumors had significantly improved survival versus controls (P = 0.05). In contrast, the A2780 p53(+) ovarian cancer xenograft was resistant to dl1520. The efficacy of i.p. dl1520 in the p53(−) models correlated strongly with tumor burden present at the time of treatment initiation, and no efficacy was seen with non-replicating/UV-inactivated dl1520. Selectively replicating viruses such as dl1520 hold promise as i.p. therapies for p53-deficient and chemotherapy-resistant ovarian carcinomas. A phase I clinical trial of i.p. dl1520 (ONYX-015) is underway in patients with cisplatin-resistant ovarian carcinoma.
67 citations
••
TL;DR: A novel linkage for the solid-phase synthesis of hydroxamic acids is described, which is stable to all reagents commonly used in Fmoc peptide synthsis and induced by treatment with trifluoroacetic acid.
66 citations
••
TL;DR: Modified HIV envelope (env) DNA vaccines derived from the South African subtype C TV1 strain are able to prime for humoral responses in rabbits and rhesus macaques, and pilot-scale production of the various TV1 DNA vaccine constructs and env proteins described here should provide an initial platform upon which to improve the immunogenicity of these sub type C HIV envelope vaccines.
Abstract: This article was written by Prof Janse van Rensburg before she joined the University of Pretoria.
66 citations
Authors
Showing all 1973 results
Name | H-index | Papers | Citations |
---|---|---|---|
Marc W. Kirschner | 162 | 457 | 102145 |
Paul Tempst | 148 | 309 | 89225 |
J. Fraser Stoddart | 147 | 1239 | 96083 |
Rino Rappuoli | 132 | 816 | 64660 |
Carl-Henrik Heldin | 131 | 520 | 67528 |
David J. Kwiatkowski | 129 | 502 | 64377 |
Graeme I. Bell | 127 | 531 | 61011 |
Anthony Cerami | 123 | 477 | 79895 |
David B. Dunger | 110 | 703 | 55784 |
Michael Simons | 106 | 401 | 38071 |
Jay A. Levy | 104 | 451 | 37920 |
Christer Betsholtz | 104 | 357 | 56771 |
Ken A. Dill | 99 | 401 | 41289 |
Michael P. Busch | 96 | 758 | 43075 |
Sung-Hou Kim | 93 | 371 | 34091 |